Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3949/ccjm.77a.10004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effectiveness and safety of adalimumab biosimilar in patients with inflammatory bowel disease.
Farm Hosp
January 2025
Servicio de Farmacia, Hospital Universitario La Plana, Castellón, España.
Background: Adalimumab biosimilar MSB11022 (Idacio®) has been approved for the same indications as its originator (Humira®), based on findings from clinical trials in plaque psoriasis. Data on its efficacy and safety in inflammatory bowel disease, however, are scarce.
Methods: Retrospective, observational study of 44 patients with inflammatory bowel disease: 30 were treated with originator adalimumab, five were directly started on MSB11022, and nine switched from originator to biosimilar adalimumab.
Phaeoisaria sp. fungal keratitis resembling corneal rust residue: a case report.
BMC Ophthalmol
January 2025
Department of Ophthalmology, Peking University Third Hospital, Beijing, China.
Background: Fungal keratitis can develop after plant injury or after prolonged glucocorticoid use. Typical manifestations include corneal infiltrates, satellite lesions, plaques, and an immune ring. Some cases exhibit atypical signs, requiring reliance on etiological examination.
View Article and Find Full Text PDFExploring the Therapeutic Landscape: A Narrative Review on Topical and Oral Phosphodiesterase-4 Inhibitors in Dermatology.
Pharmaceutics
January 2025
Department of Dermatology, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain.
Phosphodiesterase-4 (PDE4) is involved in the synthesis of inflammatory cytokines that mediate several chronic inflammatory disorders, including psoriasis and atopic dermatitis. In recent years, the therapeutic armamentarium in dermatology has expanded with the introduction of PDE4 inhibitors, both in oral and topical formulations. PDE4 inhibitors have gained increasing interest due to their remarkable safety record and ease of prescription, as evidenced by the recent influx of literature detailing its off-label uses.
View Article and Find Full Text PDFPrevalence of High-Risk CTA-Based Carotid Plaque-RADS Subtypes in Patients With Embolic Stroke of Undetermined Source.
Stroke
January 2025
Department of Neurology, University of Pennsylvania, PA. (L.I., S.E.Z., S.E.K., B.L.C.).
Background: A modified computed tomography angiography (CTA)-based Carotid Plaque Reporting and Data System (Plaque-RADS) classification was applied to a cohort of patients with embolic stroke of undetermined source to test whether high-risk Plaque-RADS subtypes are more prevalent on the ipsilateral side of stroke. With the widespread use of CTA for stroke evaluation, a CTA-based Plaque-RADS would be valuable for generalizability.
Methods: A retrospective observational cross-sectional study was conducted at a single integrated health system comprised of 3 hospitals with a comprehensive stroke center between October 1, 2015, and April 1, 2017.
SWEET'S SYNDROME ASSOCIATED WITH PHEOCHROMOCYTOMA: A RARE CASE REPORT AND REVIEW OF LITERATURE.
Acta Endocrinol (Buchar)
January 2025
Municipal Clinical Hospital - Urology, Cluj-Napoca.
Background: Sweet's syndrome (SS) or acute febrile neutrophilic dermatosis is a dermatological illness that can be described by tender erythematous plaques or nodules and acute onset fever. The etiology is multifactorial and is not fully understood. SS is separated in three subclasses: classical, malignancy-associated, and drug-induced.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!